New Delhi, March 20 Eris Lifesciences launched a generic version of Semaglutide under the brand name 'Sundae' in the country on Friday, capitalizing on the expiration of patents for molecules similar to Ozempic and Wegovy in India.The company stated that it is introducing the diabetes and...
New Delhi, February 24 Eris Lifesciences announced on Tuesday that it has partnered with Natco Pharma for the commercialization of semaglutide in India.Semaglutide, a GLP-1 receptor agonist, has emerged globally as a transformative therapy for the management of Type 2 diabetes and chronic...